A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD4954 and the Absolute Bioavailability of AZD4954

Inclusion Criteria

• Inclusion Criteria:
• - Healthy males aged 30 to 65 years inclusive
• - BMI of 18.0 to 35.0 kg/m2 inclusive
• - Regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day)
• Exclusion Criteria:
• - Serious adverse reaction or serious hypersensitivity to any drug or formulation excipients
• - Presence or history of clinically significant allergy requiring treatment
• - History of clinically significant cardiovascular, renal, hepatic, respiratory, dermatological or gastrointestinal disease, and neurological or psychiatric disorder
• - History of cholecystectomy or gall stones
• - History of GI surgery
• - Acute diarrhoea or constipation in the 7 days before the predicted Day 1
• - Participants who do not have suitable veins for multiple venepunctures/cannulation
• - Clinically significant abnormal clinical chemistry, haematology, coagulation or urinalysis
• - Evidence of renal impairment at screening
• - Participants who have received any IMP in a clinical research study within the 90 days prior to Day 1
• - Participants who have previously been administered IMP in this study
• - Radiation exposure exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years
• - Participants who have been administered IMP in an ADME study in the last 12 months
• - Donation of blood or plasma within the previous 3 months or loss of greater than 400 mL of blood
• - Use of any prescribed or non-prescribed medication including antacids, gastric pH modifying agents, analgesics, herbal remedies, vitamins and minerals within 2 weeks of dosing
• - Current smokers or known or suspected history of alcohol or drug abuse
• - Excessive intake of caffeine-containing drinks or food